We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 383

Double-patenting challenges for life sciences companies

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Perhaps more than any other technology field, patentees in the life sciences sector tend to be holders of patent families: collections of patents and

Federal Court dismisses prohibition application for quetiapine tablets SEROQUEL XR

  • Norton Rose Canada LLP
  • -
  • Canada
  • -
  • March 20 2013

AstraZeneca Canada Inc. and AstraZeneca UK Limited (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

Ontario Superior Court affirms that section 8 damages do not include disgorgement of innovator’s profits

  • Norton Rose Canada LLP
  • -
  • Canada
  • -
  • January 22 2013

This is the first proceeding under the Patented Medicine (Notice of Compliance Regulations) (“NOC Regulations”) brought by Apotex Inc. in the Ontario

Markush claims can pose a risk of patent invalidity

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

As patent law in Canada continues to evolve in significant ways, it is important to remind ourselves of cases from the past few years that continue to impact patent drafting today and to influence the validity of patents, especially pharmaceutical patents in Canada

Court affirms utility of Gleevec patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J

An end to generic claims for innovator profits?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the "NOC Regulations"

Federal court rejects PMPRB Copaxone decision on excessive prices again

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

Hospira v Eli Lilly, appeal of order for further and better production of documents, gemcitabine, October 26, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Eli Lilly alleged that gemcitabine made in China and imported into Canada by Hospira infringes Eli Lilly's patent for an intermediate process step in the manufacture of gemcitabine

Apotex Inc. v. Allergan, Inc., 2011 FCA 134, (April 14, 2011) gatifloxacin interlocutory appeal re. order dismissing request to strike out statement of claim.

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 1 2011

The Defendants appealed from an interlocutory order of a judge of the Federal Court which dismissed a request to strike out the statement of claim because it contained speculative pleas of patent infringement and it did not meet the requirements for quia timet action

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy